[3H]IVDE77, a novel radioligand with high affinity and selectivity for the insulin-regulated aminopeptidase.

[1]  P. Gard,et al.  Blockade of pro-cognitive effects of angiotensin IV and physostigmine in mice by oxytocin antagonism. , 2012, European journal of pharmacology.

[2]  P. Crack,et al.  Insulin-regulated aminopeptidase deficiency provides protection against ischemic stroke in mice. , 2012, Journal of neurotrauma.

[3]  G. Vauquelin,et al.  Angiotensin IV displays only low affinity for native insulin‐regulated aminopeptidase (IRAP) , 2012, Fundamental & clinical pharmacology.

[4]  A. Lipkowski,et al.  Radiotracers, tritium labelling of neuropeptides , 2012 .

[5]  J. Harding,et al.  Development of Angiotensin IV Analogs as Hepatocyte Growth Factor/Met Modifiers , 2012, Journal of Pharmacology and Experimental Therapeutics.

[6]  H. Jungwirth,et al.  Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System , 2012, International journal of hypertension.

[7]  M. Sim,et al.  Des-aspartate-angiotensin-I and angiotensin IV improve glucose tolerance and insulin signalling in diet-induced hyperglycaemic mice. , 2011, Biochemical pharmacology.

[8]  M. Parker,et al.  Identification and development of specific inhibitors for insulin‐regulated aminopeptidase as a new class of cognitive enhancers , 2011, British journal of pharmacology.

[9]  G. Vauquelin,et al.  Binding of “AT4 receptor” ligands to insulin regulated aminopeptidase (IRAP) in intact Chinese hamster ovary cells , 2011, Molecular and Cellular Endocrinology.

[10]  A. Hallberg,et al.  Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis. , 2011, Journal of medicinal chemistry.

[11]  G. Vauquelin,et al.  Conformational constraints in angiotensin IV to probe the role of Tyr2, Pro5 and Phe6 , 2011, Journal of peptide science : an official publication of the European Peptide Society.

[12]  R. Cherny,et al.  Regulation of insulin-regulated membrane aminopeptidase activity by its C-terminal domain. , 2011, Biochemistry.

[13]  C. Guérin,et al.  Colocalization Analysis in Fluorescence Micrographs: Verification of a More Accurate Calculation of Pearson's Correlation Coefficient , 2010, Microscopy and Microanalysis.

[14]  K. Okumura,et al.  Ablation of Angiotensin IV Receptor Attenuates Hypofibrinolysis via PAI-1 Downregulation and Reduces Occlusive Arterial Thrombosis , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Y. Michotte,et al.  Selective labeling of IRAP by the tritiated AT4 receptor ligand [3H]Angiotensin IV and its stable analog [3H]AL-11 , 2009, Molecular and Cellular Endocrinology.

[16]  A. Dupont,et al.  Renal vasoconstrictor and pressor responses to angiotensin IV in mice are AT1a-receptor mediated , 2009, Journal of hypertension.

[17]  G. Vauquelin,et al.  The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. , 2009, Journal of medicinal chemistry.

[18]  P. Vanderheyden.  From angiotensin IV binding site to AT4 receptor , 2009, Molecular and Cellular Endocrinology.

[19]  D. Tourwé,et al.  A novel solid phase approach to Aia‐containing peptides , 2009, Journal of peptide science : an official publication of the European Peptide Society.

[20]  K. Kandror,et al.  Self-assembly of Glut4 Storage Vesicles during Differentiation of 3T3-L1 Adipocytes* , 2008, Journal of Biological Chemistry.

[21]  Antony Vinh,et al.  Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma. , 2008, Atherosclerosis.

[22]  Y. Michotte,et al.  Involvement of insulin-regulated aminopeptidase in the effects of the renin–angiotensin fragment angiotensin IV: a review , 2008, Heart Failure Reviews.

[23]  P. Karoyan,et al.  Beta-homo-amino acid scan of angiotensin IV. , 2008, Journal of medicinal chemistry.

[24]  A. Albiston,et al.  Lack of Intra-cellular Signalling by Angiotensin IV in IRAP Transfected Cells , 2008, International Journal of Peptide Research and Therapeutics.

[25]  Minh Tam Le,et al.  Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]Angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme. , 2006, European journal of pharmacology.

[26]  S. Faure,et al.  Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[27]  S. Faure,et al.  Vasoconstrictive Effect of Angiotensin IV in Isolated Rat Basilar Artery Independent of AT1 and AT2 Receptors , 2005, Journal of Vascular Research.

[28]  R. Watson,et al.  Initial entry of IRAP into the insulin-responsive storage compartment occurs prior to basal or insulin-stimulated plasma membrane recycling. , 2005, American journal of physiology. Endocrinology and metabolism.

[29]  E. Block,et al.  Angiotensin IV enhances phosphorylation of 4EBP1 by multiple signaling events in lung endothelial cells , 2005, Molecular and Cellular Biochemistry.

[30]  S. Ye,et al.  What’s new in the renin-angiotensin system? , 2004, Cellular and Molecular Life Sciences CMLS.

[31]  Veerle Kersemans,et al.  Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [125I]Ang IV binding and catalytic activity. , 2004, Biochemical pharmacology.

[32]  L. Hunyady,et al.  Angiotensin IV Is a Potent Agonist for Constitutive Active Human AT1 Receptors , 2002, The Journal of Biological Chemistry.

[33]  G. Vauquelin,et al.  Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations. , 2002, Biochemical pharmacology.

[34]  Vincent J. Dupriez,et al.  Adaptation of Aequorin Functional Assay to High Throughput Screening , 2002, Journal of biomolecular screening.

[35]  R. Simpson,et al.  Evidence That the Angiotensin IV (AT4) Receptor Is the Enzyme Insulin-regulated Aminopeptidase* , 2001, The Journal of Biological Chemistry.

[36]  R. K. Handa.  J Am Soc Nephrol 11: 1377–1386, 2000 Metabolism Alters the Selectivity of Angiotensin-(1-7) Receptor Ligands for Angiotensin Receptors , 2022 .

[37]  L. Stubley,et al.  Contributions of the Brain Angiotensin IV–AT4 Receptor Subtype System to Spatial Learning , 1999, The Journal of Neuroscience.

[38]  G. Vauquelin,et al.  Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO‐K1 cells expressing human angiotensin II AT1 receptors , 1999, British journal of pharmacology.

[39]  E. Block,et al.  Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[40]  R. Ardaillou,et al.  Characterization of angiotensin IV-degrading enzymes and receptors on rat mesangial cells. , 1998, American journal of physiology. Renal physiology.

[41]  F. Tozawa,et al.  Endothelin ET(B) receptors show different binding profiles in intact cells and cell membrane preparations. , 1998, European journal of pharmacology.

[42]  J. Davison,et al.  Evaluation of enzyme inhibitors of cystinyl aminopeptidase and application to the measurement of immunoreactive atrial natriuretic peptide in human pregnancy. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[43]  J. Harding,et al.  AT4 receptor binding characteristics: d-Amino acid- and glycine-substituted peptides , 1993, Peptides.

[44]  J. Harding,et al.  Discovery of a distinct binding site for angiotensin II (3–8), a putative angiotensin IV receptor , 1992, Regulatory Peptides.

[45]  T. Schwartz,et al.  Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors , 1990, FEBS letters.

[46]  J. Engberg,et al.  Complete amino acid sequence of human intestinal aminopeptidase N as deduced from cloned cDNA , 1988, FEBS letters.

[47]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[48]  D. Seebach,et al.  Enantioselective Preparation of ߲-Amino Acid Derivatives for -Peptide Synthesis , 2009 .

[49]  Antony Vinh,et al.  Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. , 2008, Cardiovascular research.